Title: Salivary IgG antibody response against SARS-CoV-2 differs between vaccinated children and adults

Author names and affiliations: María Noel Badano[1], Irene Keitelman[1], Matías Javier Pereson[1], Natalia Aloisi[2], Florencia Sabbione[1], Patricia Baré[1,2]

[1] Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina. Postal address: J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina.
[2] Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina. Postal address: J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina.

Correspondence: María Noel Badano, Laboratorio de Patogenia de Infecciones Virales, Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA 1425, noebadano@yahoo.com.ar, +5491167586135. ORCID identifier: 0000-0002-0358-7738.

Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Funding/Support: This study was supported by a grant from CONICET (PIP 11220210100378CO).

Conflict of Interest Disclosure: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethics Statement: This study was approved by the Academia Nacional de Medicina Ethics Committee.

Consent Statement: Written informed consent was obtained from adult participants and from parents for children participants.

Abbreviations: binding antibody units (BAU) per mL (BAU/mL), geometric mean concentrations (GMC), 95% confidence intervals (95% CI).

Abstract

Studies comparing antibody responses against SARS-CoV-2 between children and adults show conflicting results in blood and are limited in the mucosa. Furthermore, as the results of studies comparing systemic and salivary immune responses are inconsistent, it is unclear whether determination of salivary antibodies against SARS-CoV-2 could be a non-invasive approach to evaluate the humoral immune response.

In this work, by studying and comparing systemic and salivary IgG antibody responses in vaccinated adults, we observed that the salivary immune response against SARS-CoV-2 in vaccinated adults largely reflects that observed at systemic levels. Higher salivary and systemic antibody concentrations were observed in adults who had schedules that included mRNA-based vaccines, a greater number of exposures, a shorter interval time between last exposure and saliva collection and had been exposed to SARS-CoV-2. Detection of salivary antibodies was associated with schedules that included mRNA-based vaccines, time between last exposure and sample collection, and systemic antibody concentrations. This suggests that salivary antibody detection might be compromised in subjects with lower systemic antibody levels.

Comparison of salivary antibody levels between vaccinated children and adults showed a stronger salivary antibody response against SARS-CoV-2 in vaccinated children. This also remained when antibody levels were compared between children and adults who had similar vaccination schedules or the same number of exposures or interval time between last exposure and saliva collection. A multivariable linear regression analysis confirmed these results showing that age, symptomatic exposure, number of vaccine doses and schedules that included mRNA-based vaccines associated with salivary anti-SARS-CoV-2 IgG antibody levels.

Determination of salivary antibodies against SARS-CoV-2 could be a non-invasive approach to evaluate the short-term immune response in children and adults with multiple exposures, especially

in settings where blood sampling cannot be fulfilled. The higher levels of salivary anti-SARS-CoV-

2 IgG antibodies observed in children align with studies reporting stronger systemic antibody

responses in children, suggesting their adaptive immune responses might be more efficient both

locally and systemically. Further studies are required to characterize the salivary microenvironment

for a better understanding of the difference observed in the local humoral immune response between

children and adults.

Keywords

SARS-CoV-2; Salivary IgG antibody response; Systemic IgG antibody response; vaccines;

children.

Introduction

While several advances have been made in the understanding of SARS-CoV-2 infection and its

associated pathology, certain aspects related to the immune response remain uncertain. The lower

availability of blood samples from children coupled with the late administration of COVID-19

vaccines in this population led to less knowledge about their immune response following infection

and vaccination in comparison to adults.

It is still debatable whether children and adults show similar systemic humoral immune responses

against SARS-CoV-2 after infection and vaccination. Studies have reported similar [1, 2], lower [3,

4] or stronger and longer-lasting [5, 6] systemic antibody responses to SARS-CoV-2 infection in

children than adults. There are also conflicting results regarding antibody responses following

vaccination, with studies showing higher [6, 7], similar [8-10] or lower [4] SARS-CoV-2-specific

antibody levels in children compared to adults.

Information about the mucosal immune response against SARS-CoV-2 in children is limited. Using saliva-based tests, the prevalence of salivary anti-SARS-CoV-2 IgG antibodies in unvaccinated and vaccinated children has been studied [11-13], further showing that salivary antibody levels increase following infection or exposure [12, 14] and vaccination [13]. However, studies comparing salivary antibody responses against SARS-CoV-2 between children and adults have yielded contradictory results, showing higher [15] or lower [4] salivary antibody levels in children than in adults. On the other hand, results from studies comparing systemic and salivary humoral immune responses to SARS-CoV-2 are inconsistent. While several studies have shown a positive correlation between systemic and salivary anti-SARS-CoV-2 IgG antibody levels in both adults [16-18] and children [11, 15], other studies have shown a weak correlation [19, 20]. We have also previously shown that SARS-CoV-2 breakthrough infections in vaccinated adults boost antibody levels not only in the blood but also in the salivary compartment [21]. Therefore, although several studies have demonstrate the validity of the determination of specific salivary antibodies as indicators of seroconversion after natural infection or vaccination [16-18, 22], is still unclear whether saliva could be used as an alternative to blood for the determination of antibodies against SARS-CoV-2. In this work we investigated and compared the systemic and salivary IgG antibody responses against SARS-CoV-2 in vaccinated adults, to analyze whether the determination of salivary antibodies against SARS-CoV-2 could be a non-invasive approach to evaluate the humoral immune response following infection or vaccination. Salivary antibody levels were also compared between vaccinated children and adults to analyze whether the specific humoral immune response differed within the salivary compartment.

Materials and methods

Study Design, Participants and Samples

The results of adults presented in this study are part of an ongoing observational prospective cohort

study started at the beginning of the pandemic among healthcare workers from the Academia

Nacional de Medicina, to study the humoral immune response against SARS-CoV-2 after

vaccination and/or infection. The results of the children included in this work are part of an

observational cohort study started on February 2022 to analyze the prevalence of salivary anti-

SARS-CoV-2 IgG antibodies in children.

Blood and saliva sample pairs ($n = 101$) from adults who had received the primary vaccination

schedule and a booster dose were collected between December 2021-November 2022. Saliva

samples ($n = 80$) from children up to 18 years old who had received two or three vaccine doses

were collected between February-August 2022. The median time between last exposure to SARS-

CoV-2 antigens (through vaccination, infection or exposure) and sample collection for all samples

was 58 (21-270), for adult samples was 50 (21-234) and for children's samples was 77 (21−270)

days (Table 1).

In both adults and children, samples were obtained from unexposed individuals and from those who

were exposed to SARS-CoV-2 at any stage of vaccination. Exposed subjects included those with

confirmed past SARS-CoV-2 infection and those who were household contacts. All subjects with

confirmed past SARS-CoV-2 infection had mild disease based on the World Health Organization

classification [23]. Among adults, 49/101 had a confirmed past SARS-CoV-2 infection, 3/101 were

household contacts and 49/101 were unexposed subjects. 11/49 of the infected subjects and 3/3

household contacts were exposed before the Omicron variant circulated in Argentina. The

remaining 38/49 subjects were infected when the only circulating variant in Argentina was

Omicron. Among children, 11/80 had a confirmed past SARS-CoV-2 infection, 35/80 were

household contacts and 34/80 were unexposed subjects. 13/46 of the children who have been

infected/household contacts were exposed before the Omicron variant circulated in Argentina, while

the remaining 33/46 children were exposed when Omicron was the only circulating variant in

Argentina. Of the adults exposed to SARS-CoV-2, 48/52 had mild symptoms, while 4/52 reported

no symptoms. Of the SARS-CoV-2 exposed children, 26/46 reported mild symptoms, while 20/46

had no symptoms.

Information regarding demographic characteristic, SARS-CoV-2 exposure and vaccination

schedules are detailed in Table 1. Vaccines from the same platform were administered on similar

dates and with similar interval time between doses. This study was approved by the Academia

Nacional de Medicina Ethics Committee.

Written informed consent was obtained from adult participants and from parents for children

participants.

Sample collection and processing

Plasma or serum samples were obtained immediately after centrifugation of the peripheral blood

and stored in aliquots at −20ºC until used. For saliva sampling, individuals spat their first saliva of

the day into a tube, without drinking, brushing teeth or eating, before collection. Saliva samples

were centrifuged at 17,000 x *g* for 10 min (4°C) and the supernatant was stored at −20°C until used.

SARS-CoV-2 Antibody ELISA

Detection of anti-spike SARS-CoV-2 IgG antibodies both in blood and saliva was performed by

ELISA (COVIDAR-IgG, Laboratorios Lemos S.R.L, Buenos Aires, Argentina). The plates of the

assay are coated with a purified mixture of the spike protein and the receptor binding domain

(RBD) of the SARS-CoV-2 from the original viral variant from Wuhan (GenBank: MN908947).

Determination of specific antibodies in blood was performed following the manufacturer's

instructions [21]. Determination of salivary antibodies was performed with the conditions we had

previously established for the salivary measurements [21]. Basically, salivary IgG anti-spike

antibodies were determined following the manufacturer's instructions, without performing the first

sample dilution. Antibody concentrations in binding antibody units (BAU) per mL (BAU/mL) were

obtained by interpolating the OD 450 nm values of the samples into a calibration curve performed

with the provided standard (400 BAU/mL).

Statistical Analysis

Data analyses were performed using the GraphPad 10.2.3 Prism software (GraphPad Software, San

Diego, CA, USA). Geometric mean concentrations (GMC) of specific antibody levels with 95%

confidence intervals (95% CI) were calculated. Antibody levels between groups were compared

with Mann-Whitney test. The Spearman coefficient of rank correlation was used to assess the

correlation between specific salivary and blood antibodies. A multivariable linear regression model

was performed with age, sex, symptomatic exposure, number of vaccine doses, number of

exposures, vaccination schedules that included mRNA-based vaccines, time between most recent

antigen exposure and sample collection as independent variables and salivary antibody levels as

dependent variable. The linear regression coefficients (β) with 95% CI were calculated. In all cases,

a value of $p < 0.05$ was considered indicative of a significant difference.

Results

IgG specific salivary and blood antibody responses in vaccinated adults

Specific antibodies were detected in 100% of blood samples (GMC BAU/mL, 95% CI: 3154,

2461−4043) and in 82% of saliva samples (GMC BAU/mL, 95% CI: 67.0, 42.8−104.7). Subjects

with higher systemic antibody levels (≥GMC: 3154 BAU/mL) also showed higher salivary antibody

concentrations than those with lower systemic antibody levels (GMC BAU/mL, 95% CI, Saliva:

156.8, 92.7−265.2 *vs* 24.2, 11.1−52.7; *p*< 0.001). Furthermore, higher systemic antibody levels

were found in subjects with detectable salivary antibodies compared to those without detectable

salivary antibodies (GMC BAU/mL, 95% CI, Blood: 3841, 2979−4952 *vs* 1316, 701.1−2469; *p*<

0.01) (Figure 1A-D). Specific antibody levels in blood and saliva were positively correlated (*r*=

0.5, *p*<0.0001).

Therefore, we analyzed how variables previously reported to be associated with systemic anti-

SARS-CoV-2 IgG antibody levels, relate to antibody levels in both the blood and the salivary

compartment. As we observed similar results among subjects who received one or two doses of

mRNA-based vaccines, they were combined into a single group (non-mRNA + mRNA (3d)) for the

presentation of the results. Levels of anti-spike SARS-CoV-2 IgG antibodies were higher in

subjects who received three doses of schedules that included mRNA-based vaccines (non-mRNA +

mRNA (3d)) compared to those observed in individuals who received three doses of schemes not

including mRNA-based vaccines (non-mRNA (3d)) (GMC BAU/mL, 95% CI, Blood: 6335,

3990−10058 *vs* 2494, 1875−3318; *p*< 0.01; Saliva: 183.3, 106.5−315.6 *vs* 47.2, 27.1−82.2; *p*< 0.01)

(Figure 1A). Subjects with a greater number of exposures to SARS-CoV-2 antigens (through

vaccination, infection or exposure) showed higher antibody concentrations than those with a lower

number of exposures (GMC BAU/mL, 95% CI, Blood: 5586, 4237−7365 *vs* 1615, 1162−2245; *p*<

0.0001; Saliva: 99.0, 52.6−186.4 *vs* 43.2, 23.5−80.0; *p*< 0.01) (Figure 1B). Antibody concentrations

decreased as the interval time between last exposure and sample collection increased (GMC

BAU/mL, 95% CI, Blood: 5448, 4087−7263 *vs* 1847, 1305−2614; *p*< 0.0001; Saliva: 179.3,

113.3−283.7 *vs* 22.0, 11.1−43.5; *p*< 0.0001) (Figure 1C). Subjects exposed to SARS-CoV-2 showed

higher antibody levels than those unexposed (GMC BAU/mL, 95% CI, Blood: 5183, 3871−6940 *vs*

1807, 1275−2561; *p*< 0.0001; Saliva: 104.5, 54.8−200.0 *vs* 42.9, 23.6−78.0; *p*< 0.01) (Figure 1D).

Using Fisher's exact test, detection of specific antibodies in saliva was associated with schedules

that included mRNA-based vaccines ($p< 0.05$; OR=7.8) (Figure 1A), the time between last exposure

and sample collection ($p< 0.001$; OR=7.8) (Figure 1C) and systemic antibody concentrations ($p<$

0.01; OR=7.1) (Figure 1A-D).

Comparison of IgG specific salivary antibody responses between vaccinated children

and adults

Considering all samples, higher salivary antibody concentrations were observed in children

compared to adults (GMC: 104.0 BAU/mL, 95% CI: 58.7−184.1 *vs* 66.0 BAU/mL, 95% CI:

42.8−104.7; $p< 0.05$). No significant differences were found in antibody levels between adults

receiving three doses of non-mRNA-based vaccines (non-mRNA (3d)) and children receiving two

doses of non-mRNA-based vaccines (GMC: 47.2 BAU/mL, 95% CI: 27.1−82.2 *vs* 27.3 BAU/mL,

95% CI: 13.7−54.3; $p=0.3$). However, antibody levels in adults who received three doses of

schedules that included mRNA-based vaccines (non-mRNA + mRNA (3d)) (GMC: 183.3

BAU/mL; 95% CI: 106.5−315.6) were higher than in children who received two doses of non-

mRNA vaccines ($p< 0.001$). Children who received three doses of mRNA vaccines (mRNA (3d))

(GMC: 486.0 BAU/mL; 95% CI: 220.7–1069) or two doses of a non-mRNA-based vaccine plus

one dose of an mRNA-based vaccine (non-mRNA + mRNA (3d)) (GMC: 1997 BAU/mL; 95% CI:

878.6–4538) showed higher antibody concentrations than adults who received three doses of

schedules that did or did not include mRNA-based vaccines ($p< 0.01$) (Figure 2A). Salivary

antibody concentrations were higher in children who had three exposures compared to adults who

had three exposures (GMC: 138.4 BAU/mL, 95% CI: 64.3−298.0 *vs* 43.2 BAU/mL, 95% CI:

23.5−80.0; $p< 0.001$) (Figure 2B). Children who had four exposures (GMC: 495.3 BAU/mL; 95%

CI: 178.2–1377) showed higher antibody levels than adults who had three or four exposures (GMC:

99.0 BAU/mL; 95% CI: 52.6–186.4) ($p< 0.001$) (Figure 2B). Antibody concentrations were higher

in children compared to adults who had the same interval time (≤58 days) between last exposure

and saliva collection (GMC: 396.0 BAU/mL, 95% CI: 185.8−844.1 vs GMC: 156.3 BAU/mL, 95%

CI: 98.0−249.6; $p< 0.01$) (Figure 2C). Unexposed adults showed lower antibody levels than

exposed children (GMC BAU/mL, 95% CI: 42.9, 23.6−78.0 vs 150.8, 74.5−305.5; $p< 0.001$)

(Figure 2D). Age ($\beta1$: -24.6, 95% CI: -39.2−-9.9; $p< 0.001$), symptomatic exposure ($\beta2$: 871.7,

95% CI: 249.5−1494; $p< 0.01$), number of vaccine doses ($\beta3$: 881.4, 95% CI: 90.5−1672; $p< 0.05$)

and schedules that included mRNA-based vaccines ($\beta4$: 726.0, 95% CI: 189.5−1263; $p< 0.01$)

associated with salivary antibody levels in a multivariable linear regression analysis ($p< 0.0001$).

Discussion

Data from studies comparing antibody responses against SARS-CoV-2 after infection or

vaccination between children and adults are conflicting in blood [1-10] and limited in mucosa [4,

15]. On the other hand, as studies comparing systemic and salivary humoral immune responses to

SARS-CoV-2 have yielded contradictory results [11, 15, 16-22], it remains yet to be determined

whether saliva could be used as an alternative to blood for the determination of antibodies against

SARS-CoV-2.

In this work, we investigated and compared the systemic and salivary IgG antibody responses

against SARS-CoV-2 in vaccinated adults. Analysis of different variables previously reported to be

related to systemic anti-SARS-CoV-2 IgG antibody levels showed similar results for blood and

saliva. Higher antibody concentrations were observed in both the blood and saliva of adults who

had schedules that included mRNA-based vaccines, a greater number of exposures, a shorter

interval time between last antigens exposure and saliva collection and had been exposed to SARS-

CoV-2. Furthermore, a positive correlation was found between systemic and salivary anti-SARS-

CoV-2 IgG antibody levels, with higher salivary antibody concentrations observed in subjects with

higher systemic antibody levels. However, specific antibodies were detected in 100% of blood

samples and in 82% of saliva samples. Detection of specific salivary antibodies was associated with

schedules that included mRNA-based vaccines, time between last exposure and sample collection,

and systemic antibody concentrations. These results, together with the fact that most subjects

without detectable salivary antibodies showed lower systemic antibody levels, suggest that salivary

antibody detection would appear to depend on variables that influence systemic antibody levels.

Therefore, although our results showed that the salivary immune response against SARS-CoV-2 in

vaccinated adults largely reflects that observed at systemic levels, salivary antibody detection might

be compromised in subjects presenting lower systemic antibody concentrations. This is in

agreement with previously reported results showing that salivary antibody responses were mainly

detected in subjects showing higher serum antibody levels [24]. However, we observed that the

prevalence of salivary antibodies was high in both adults (82%) and children (81%) [12], unlike to

that previously reported in unvaccinated infected subjects [11, 13, 24] but in agreement with those

reported in vaccinated subjects [13, 18, 22], suggesting that multiple exposures are required to

enhance systemic antibody levels and allow salivary antibody detection.

Salivary antibody concentrations were also compared between vaccinated children and adults to

analyze whether specific antibody responses differed within the salivary compartment. We observed

a higher salivary antibody response against SARS-CoV-2 in vaccinated children compared to

adults. This also remained when antibody levels were compared between children and adults who

had similar vaccination schedules (three doses combining mRNA and non-mRNA based vaccines)

or the same number of exposures. Furthermore, when considering the same interval time between

last exposure and saliva collection, children also showed higher antibody concentrations than adults.

Higher antibody levels were also observed in children exposed to SARS-CoV-2 compared to

unexposed adults. These results were confirmed in a multivariable linear regression analysis,

showing that age, symptomatic exposure, number of vaccine doses and schedules that included

mRNA-based vaccines were associated with salivary anti-SARS-CoV-2 IgG antibody levels.

The biological and molecular basis for a favorable outcome after SARS-CoV-2 infection in children

compared to adults is not fully understood. Several hypotheses have tried to explain the milder

presentation of the disease in children, including a protective role of pre-existing cross-reactive

antibodies against seasonal coronaviruses, a lower expression of the angiotensin-converting enzyme

2 (ACE2) and a less propensity to develop an exacerbated pro-inflammatory response, among

others [25]. Furthermore, it is not entirely clear the relative contribution of the antibody response to

SARS-CoV-2 to the favorable outcome in the pediatric population. In the current work, we showed

that children had higher salivary anti-SARS-CoV-2 IgG antibody concentrations than adults. Given

that mucosal immunity plays a key role in prevention and early defense against infection, being the

entry route for the virus and the site of first encounter with the immune response, it is tempting to

speculate that the stronger salivary antibody response observed in children could help prevent or

limit infection, thus contributing to the favorable outcome observed in the pediatric population.

As salivary IgG is derived primarily from circulating IgG through transudation [26] and the salivary

IgG response in adults highly reflects the systemic antibody response, it is very likely that the

salivary antibody response observed in children also largely reflects that present in blood. However,

given that there is also some local IgG production, we cannot rule out that a difference in the local

immune response mounted may also account to the observed difference in the salivary antibody

response against SARS-CoV-2 between children and adults.

Limitations of this study include the lack of information on the systemic antibody response in

children, which precluded direct comparison between the systemic and salivary immune responses

in children. We had no information on neutralization titers and specific IgA antibody responses in

both blood and saliva. Besides, for reasons inherent to the vaccination policies in our country, adults

mainly received non-mRNA based primary vaccination schedules and children only received

mRNA vaccines as third doses. Therefore, a comparison could not be made with samples from

adults vaccinated with three doses of mRNA vaccines or from children vaccinated with three doses

of non-mRNA-based vaccines. Despite this, we observed that among subjects who received three

vaccine doses, children who only received one dose of mRNA-based vaccine showed higher

salivary antibody concentrations than adults who also received one or even two doses of mRNA-

based vaccines, suggesting that other factors inherent to children, in addition to the vaccination

schedules received, could be contributing to the higher salivary antibody response observed in

children. Information about SARS-CoV-2 variants involved in the infections/exposures and their

association with antibody levels was not available. However, most infections/exposures both in

adults and children occurred when the only circulating variant in Argentina was Omicron.

Altogether, our results showed that the salivary immune response against SARS-CoV-2 in

vaccinated adults largely reflects that observed at systemic levels. However, salivary antibody

detection might be compromised in subjects with low systemic antibody concentrations, which

could be related to lower immune stimulation resulting from less immunogenic vaccines, fewer

exposures, or excessive time since last exposure, potentially leading to false negative results

compared to blood. Nevertheless, since saliva sampling is non-invasive and allows self-collection

unlike blood sampling, salivary antibody determination could be performed as an initial screening

to evaluate the immune response against SARS-CoV-2, and in those subjects who do not show

detectable salivary antibodies, determination of antibodies in blood should be performed whenever

possible. Besides, as salivary immune response is indicative of the systemic antibody response,

salivary antibody determination could guide vaccination strategies through the administration of

booster doses in those subjects who lack detectable salivary antibodies, so that they can achieve

high systemic antibody levels. In conclusion, the determination of salivary antibodies against

SARS-CoV-2 could be a non-invasive approach for the evaluation of the short-term immune

response in subjects with multiple exposures, either resulting from vaccination combined with

infection or from the administration of immunogenic vaccination schedules, both in the adult and

pediatric population, especially in settings where blood sampling cannot be fulfilled.

Furthermore, the higher levels of salivary anti-SARS-CoV-2 IgG antibodies observed in children

are in agreement with studies reporting stronger systemic antibody responses in the pediatric

population. This suggests that children could have more efficient adaptive immune responses, both

at local and systemic levels, compared to adults. Additional studies focusing on the characterization

of the salivary microenvironment are required for a better understanding of the difference observed

in the local humoral immune response between children and adults.

Acknowledgments

The authors thank all enrolled children and adults for their participation in this study. Some aspects

of this work could not have been fulfilled without the generous contribution of the IIHEMA and the

Academia Nacional de Medicina, who provide financial support to our ongoing research. This study

was supported by a grant from CONICET (PIP 11220210100378CO).

372 References

1. Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin WH, Wontakal S, et al. Distinct antibody responses to SARS-

CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. 2021;22(1):25-31. doi:

10.1038/s41590-020-00826-9.

2. Toh ZQ, Higgins RA, Do LAH, Rautenbacher K, Mordant FL, Subbarao K, Dohle Ket al. Persistence of SARS-

CoV-2-Specific IgG in Children 6 Months After Infection, Australia. Emerg Infect Dis. 2021;27(8):2233-2235. doi:

10.3201/eid2708.210965.

3. Hachim A, Gu H, Kavian O, Mori M, Kwan MYW, Chan WH, et al. SARS-CoV-2 accessory proteins reveal

distinct serological signatures in children. Nat Commun. 2022;13(1):2951. doi: 10.1038/s41467-022-30699-5.

4. Padoan A, Cosma C, Di Chiara C, Furlan G, Gastaldo S, Talli I, et al. Clinical and Analytical Performance of

ELISA Salivary Serologic Assay to Detect SARS-CoV-2 IgG in Children and Adults. Antibodies (Basel). 2024

Jan;13(1):6. doi: 10.3390/antib13010006.

5. Dowell AC, Butler MS, Jinks E, Tut G, Lancaster T, Sylla P, et al. Children develop robust and sustained cross-

reactive spike-specific immune responses to SARS-CoV-2 infection. Nat Immunol. 2022;23(1):40-49. doi:

10.1038/s41590-021-01089-8.

6. Kim M, Cheng WA, Congrave-Wilson Z, Marentes Ruiz CJ, Turner L, et al. Comparisons of Pediatric and Adult

SARS-CoV-2-Specific Antibodies up to 6 Months after Infection, Vaccination, or Hybrid Immunity. J Pediatric

Infect Dis Soc. 2024;13(1):91-99. doi: 10.1093/jpids/piad107.

7. Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Vanichsetakul P, Thonginnetra S, Niemsorn K, et al.

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai

Population: An Immunobridging Study. Vaccines (Basel). 2022 ;10(5):807. doi: 10.3390/vaccines10050807.

8. Rosa Duque JS, Wang X, Leung D, Cheng SMS, Cohen CA, Mu X, et al. Immunogenicity and reactogenicity of

SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. Nat Commun. 2022;13(1):3700. doi:

10.1038/s41467-022-31485-z.

9.   Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19

vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.

Lancet Infect Dis. 2022;22(2):196-208. doi: 10.1016/S1473-3099(21)00462-X.

10.   Li G, Cappuccini F, Marchevsky NG, Aley PK, Aley R, Anslow R, et al. Safety and immunogenicity of the

ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2

single-blind, randomised, controlled trial. Lancet. 2022;399(10342):2212-2225. doi: 10.1016/S0140-

6736(22)00770-X.

11.   Keuning MW, Grobben M, Bijlsma MW, Anker B, Berman-de Jong EP, Cohen S, et al. Differences in systemic and

mucosal SARS-CoV-2 antibody prevalence in a prospective cohort of Dutch children. Front Immunol.

2022;13:976382. doi: 10.3389/fimmu.2022.976382.

12.   Badano MN, Duarte A, Salamone G, Sabbione F, Pereson M, Chuit R, et al. Prevalence of salivary anti-SARS-CoV-

2 IgG antibodies in vaccinated children. Immunology. 2023;169(3):384-387. doi: 10.1111/imm.13656.

13.   Conti MG, Piano Mortari E, Nenna R, Pierangeli A, Sorrentino L, Frasca F, et al. SARS-CoV-2-specific mucosal

immune response in vaccinated versus infected children. Front Cell Infect Microbiol. 2024;14:1231697. doi:

10.3389/fcimb.2024.1231697.

14.   Thomas AC, Oliver E, Baum HE, Gupta K, Shelley KL, Long AE, et al. Evaluation and deployment of isotype-

specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults. Commun

Med (Lond). 2023;3(1):37. doi: 10.1038/s43856-023-00264-2.

15.   Dobaño C, Alonso S, Vidal M, Jiménez A, Rubio R, Santano R, et al. Multiplex Antibody Analysis of IgM, IgA and

IgG to SARS-CoV-2 in Saliva and Serum From Infected Children and Their Close Contacts. Front Immunol.

2022;13:751705. doi: 10.3389/fimmu.2022.751705.

16.   Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to

SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5(52):eabe5511. doi:

10.1126/sciimmunol.abe5511.

17.   Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et al. COVID-19 Serology at Population

Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. J Clin Microbiol. 2020;59(1):e02204-20. doi:

10.1128/JCM.02204-20.

18.   Healy K, Pin E, Chen P, Söderdahl G, Nowak P, Mielke S, et al. Salivary IgG to SARS-CoV-2 indicates

seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. Med.

2022;3(2):137-153.e3. doi: 10.1016/j.medj.2022.01.001.

19.   Darwich A, Pozzi C, Fornasa G, Lizier M, Azzolini E, Spadoni I, et al. BNT162b2 vaccine induces antibody release

in saliva: a possible role for mucosal viral protection? EMBO Mol Med. 2022;14(5):e15326. doi:

10.15252/emmm.202115326.

20.   Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, Ietto G, Iovino D, et al. Mucosal immune response in

BNT162b2 COVID-19 vaccine recipients. EBioMedicine. 2022;75:103788. doi: 10.1016/j.ebiom.2021.103788.

21.   Badano MN, Pereson MJ, Sabbione F, Keitelman I, Aloisi N, Chuit R, et al. SARS-CoV-2 Breakthrough Infections

after Third Doses Boost IgG Specific Salivary and Blood Antibodies. Vaccines (Basel). 2023;11(3):534. doi:

10.3390/vaccines11030534.

22.   Ketas TJ, Chaturbhuj D, Portillo VMC, Francomano E, Golden E, Chandrasekhar S, et al. Antibody Responses to

SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathog Immun. 2021;6(1):116-134. doi:

10.20411/pai.v6i1.441.

23.   World Health Organization. Clinical management of COVID-19: living guideline (WHO/2019-

nCoV/clinical/2023.2). Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2023.2

(Accessed October 7, 2024).

24.   Faustini SE, Jossi SE, Perez-Toledo M, Shields AM, Allen JD, Watanabe Y, et al. Development of a high-sensitivity

ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva.

Immunology. 2021;164(1):135-147. doi: 10.1111/imm.13349.

25.   Falahi S, Abdoli A, Kenarkoohi A. Claims and reasons about mild COVID-19 in children. New Microbes New

Infect. 2021;41:100864. doi: 10.1016/j.nmni.2021.100864.

26.   Brandtzaeg P. Secretory immunity with special reference to the oral cavity. J Oral Microbiol. 2013;5. doi:

10.3402/jom.v5i0.20401.

Figure legends

Figure 1. Systemic and salivary antibody responses against SARS-CoV-2 in vaccinated adults.
Blood and salivary anti-SARS-CoV-2 antibody levels were analyzed in vaccinated adults
according to: vaccination schedules (A), number of exposures (B), time between last exposure and
sample collection (C), exposure to SARS-CoV-2 (D). IgG anti-spike antibody concentrations
(BAU/mL) with geometric means are shown. Dotted line indicates the assay detection limit (4.03
BAU/mL). Subjects with detectable salivary antibodies (white circles or squares) and those without
detectable salivary antibodies (black circles or squares) are shown. p values were determined by
Mann-Whitney test.

**Figure 2. Comparison of salivary antibody responses against SARS-CoV-2 between
vaccinated children and adults.** Salivary anti-SARS-CoV-2 antibody levels were compared
between vaccinated adults and children according to: vaccination schedules (A), number of
exposures (B), time between last exposure and sample collection (C), exposure to SARS-CoV-2
(D). IgG anti-spike antibody concentrations (BAU/mL) with geometric means are shown. Dotted
line indicates the assay detection limit (4.03 BAU/mL). p values were determined by Mann-
Whitney test.

Table 1. Characteristics of children and adults

	Children (n=80)	Adults (n=101)
General characteristics		
Age, median (range), y	10 (4−17)	46 (27-83)
Sex		
Female, No. (%)	39/80 (49)	71/101 (70)
Male, No. (%)	41/80 (51)	30/101 (30)
Exposure to SARS-CoV-2		
Unexposed, No. (%)	34/80 (42.5)	49/101 (48.5)
Confirmed past SARS-CoV-2 infection, No. (%)	11/80 (13.75)	49/101 (48.5)
Household contacts, No. (%)	35/80 (43.75)	3/101 (3)
Infected/household contacts with COVID-19 compatible symptoms, No. (%)	26/46 (56)	48/52 (92)
Vaccination schedules non-mRNA-based		
BBIBP-CorV x 2, No. (%)	46/80 (57.5)	
BBIBP-CorV x 2 + ChAdOx1 nCoV-19 x 1, No. (%)	−	62/101 (61)
Sputnik V x 2 + ChAdOx1 nCoV-19 x 1, No. (%)	−	8/101 (8)
ChAdOx1 nCoV-19 x 3, No. (%)	−	4/101 (4)
Vaccination schedules mRNA-based		
BNT162b2 mRNA x 3, No. (%)	17/80 (21)	−
BNT162b2 mRNA x 2 + mRNA-1273 x 1, No. (%)	4/80 (5)	−
BBIBP-CorV x 2 + BNT162b2 mRNA x1, No. (%)	11/80 (14)	7/101 (7)
BBIBP-CorV x 2 + mRNA-1273 x 1, No. (%)	2/80 (2.5)	−
Sputnik V x 2 + BNT162b2 mRNA x1, No. (%)	−	5/101 (5)
ChAdOx1 nCoV-19 x 2+ BNT162b2 mRNA x1, No. (%)	−	3/101 (3)
Sputnik V x 1 + mRNA-1273 x 2, No. (%)	−	12/101 (12)
Number of exposures		
Two vaccine doses (2X), No. (%)	22/80 (27.5)	−
Two vaccine doses plus one infection/exposure (3X), No. (%)	22/80 (27.5)	−
Three vaccine doses (3X), No. (%)	12/80 (15)	46/101 (45.5)
Two vaccine doses plus two exposures (4X), No. (%)	2/80 (2.5)	−
Three vaccine doses plus one infection/exposure (4X), No. (%)	22/80 (27.5)	55/101 (54.5)
Time between most recent antigen exposure and sample collection, median (range), days	77 (21−270)	50 (21-234)
Time between most recent antigen exposure and sample collection, median (range), days	58 (21-270)	

BBIBP-CorV (Sinopharm); BNT162b2 mRNA (Pfizer–BioNTech); mRNA-1273 (Moderna).